Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Aminomethylbenzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.57 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.57 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.48 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.48 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ABAT | P80404 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminomethylbenzoic Acid SCHEMBL7428232 | 1.00 | ALDH1A1 (0.58) | ALDH1A1HDAC3HDAC6NCOR2TP53 | |
| Aminomethylbenzoic Acid SCHEMBL38758 | 0.98 | ALDH1A1 (0.60) | ALDH1A1HDAC3HDAC6NCOR2TP53 | |
| Aminomethylbenzoic Acid SCHEMBL9344424 | 0.98 | ALDH1A1 (0.60) | ALDH1A1HDAC3HDAC6NCOR2TP53 | |
| Aminomethylbenzoic Acid SCHEMBL1567841 | 0.95 | ALDH1A1 (0.58) | ALDH1A1HDAC3HDAC6NCOR2TP53 | |
| Aminomethylbenzoic Acid SCHEMBL28342619 | 0.95 | ALDH1A1 (0.58) | ALDH1A1HDAC3HDAC6NCOR2TP53 | |
| Hydrochloric Acid SCHEMBL1853914 | 0.94 | HRH3 (0.58) | ALDH1A1HDAC3HDAC6NCOR2LOXL2 | |
| Aminomethylbenzoic Acid SCHEMBL11755138 | 0.93 | ALDH1A1 (0.61) | ALDH1A1HDAC3HDAC6NCOR2TP53 | |
| SCHEMBL1851387 | 0.91 | HRH3 (0.61) | ALDH1A1HDAC3HDAC6NCOR2TP53 | |
| Aminomethylbenzoic Acid SCHEMBL29271526 | 0.91 | ALDH1A1 (0.59) | ALDH1A1HDAC3HDAC6NCOR2TP53 | |
| SCHEMBL26112100 | 0.91 | SRD5A2 (0.58) | ALDH1A1HDAC3HDAC6NCOR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115806503-B | Selective histone deacetylase inhibitor and preparation method and application thereof | 中国海洋大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-115784986-A | HDAC6 inhibitor and preparation method and application thereof | 中国海洋大学 | 2023-03-14 | — | — | CN | disclosed |
| CN-110627801-B | HDAC inhibitor and application thereof | 安徽中医药大学 | 2021-07-02 | — | — | CN | disclosed |
| WO-2021065980-A1 | BET DEGRADER | 協和キリン株式会社 | 2021-04-08 | — | — | WO | disclosed |
| CN-107325127-B | Chelated PSMA inhibitors | 癌靶技术有限责任公司 | 2020-09-01 | — | — | CN | disclosed |
| CN-110627801-A | HDAC inhibitor and application thereof | 安徽中医药大学 | 2019-12-31 | — | — | CN | disclosed |
| WO-2019189778-A1 | COMPOUND WITH ANTICANCER ACTIVITY | 協和発酵キリン株式会社 | 2019-10-03 | — | — | WO | disclosed |
| CN-106458859-B | Novel EP4 agonists as therapeutic compounds | 阿勒根公司 | 2019-08-30 | — | — | CN | disclosed |
| CN-109890821-A | Amino-pyrrolopyrimidine ketone compound and its application method | 艾科尔公司 | 2019-06-14 | — | — | CN | disclosed |
| CN-109641975-A | Method for cracking amido bond | 高德美股份公司 | 2019-04-16 | — | — | CN | disclosed |
| WO-2004083207-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2004-09-30 | — | — | WO | disclosed |
| EP-1434585-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030144274-A1 | Alkyne matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003032999-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
| EP-1073624-A1 | AMINOMETHYL-BENZOIC ESTER DERIVATIVES AS TRYPTASE INHIBITORS | Proteus Molecular Design Limited (GB) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055661-A1 | AMINOMETHYL-BENZOIC ESTER DERIVATIVES AS TRYPTASE INHIBITORS | PROTEUS MOLECULAR DESIGN LIMITED (GB) | 1999-11-04 | — | — | WO | disclosed |
| US-5468888-A | Lupane derivatives, their preparation and the pharmaceutical compositions which contain them | RHONE-POULENC RORER S.A. (FR) | 1995-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | HDAC3 1632/4885HDAC6 1892/4885CA2 4572/4885 |
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | HDAC3 1512/4885HDAC6 932/4885CA2 3109/4885 |
| US-20030144274-A1 | Alkyne matrix metalloproteinase inhibitors | MMP11, MMP13, MMP3 | HDAC3 228/4885HDAC6 251/4885CA2 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.